无明确诊断患者的心脏肌钙蛋白升高与长期预后
基于SWEDEHEART注册的回顾性队列研究纳入48,872例疑似急性冠脉综合征但出院时无明确诊断的急性入院患者,按肌钙蛋白是否超过99百分位及三分位分层。20.1%患者肌钙蛋白升高,中位随访4.9年,15.4%发生主要不良事件,肌钙蛋白越高风险越高,最高三分位风险比2.59,无心血管合并症等亚组风险比3.57。
要点
- 肌钙蛋白升高与心血管及非心血管合并症相关,并预测主要不良事件。
- 无明确诊断患者中肌钙蛋白升高不应称为「troponinemia」,需仔细评估。
- 最高三分位肌钙蛋白患者主要不良事件风险比为2.59。
核心结论
- 肌钙蛋白升高与心血管和非心血管合并症相关,并预测无明确诊断急性入院患者的主要不良事件。
- 「troponinemia」一词淡化了风险,应避免使用,此类患者需仔细检查。
研究设计与样本
- 回顾性注册队列研究,基于SWEDEHEART注册,纳入48,872例疑似急性冠脉综合征但出院无明确诊断的急性入院患者。
- 按肌钙蛋白是否超过检测特异性99百分位及高于99百分位时的检测特异性三分位分层。
主要发现
- 9,800例(20.1%)患者肌钙蛋白超过99百分位。
- 心血管危险因素及心血管和非心血管合并症患病率随肌钙蛋白分层升高而增加。
- 7,529例(15.4%)发生主要不良事件(全因死亡、心肌梗死、心衰再入院或卒中的复合终点),中位随访4.9年。
- 主要不良事件风险与更高肌钙蛋白分层相关,最高三分位风险比2.59(95%CI 2.39-2.80)。
- 无心血管合并症、肾功能不全、左室功能障碍或显著冠脉狭窄的患者中风险比3.57(95%CI 2.30-5.54)。
临床怎么用
- 对无明确诊断的急性入院患者,肌钙蛋白升高应视为风险标志,需仔细查明病因。
- 避免使用「troponinemia」等淡化术语,应结合合并症和肌钙蛋白水平评估长期风险。
局限性
- 回顾性注册研究设计可能存在残留混杂。
- 仅纳入疑似急性冠脉综合征患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiac troponin (cTn) elevation is a common finding in acutely admitted patients, even in the absence of acute coronary syndrome. In some of these patients, no etiology of cTn elevation can be identified. The term troponinemia is sometimes used to describe this scenario. OBJECTIVES: This study aimed to investigate the associations of cTn levels with clinical findings and long-term outcome in acutely admitted patients with suspected acute coronary syndrome who had been discharged without a specified diagnosis. METHODS: Retrospective registry-based cohort study investigating 48,872 patients (SWEDEHEART [Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies] registry). Patients were stratified into cohorts with cTn levels less than or equal to the assay-specific 99th percentile and separated by assay-specific cTn tertiles in case of higher levels. RESULTS: A cTn level >99th percentile was noted in 9,800 (20.1%) patients. The prevalence of cardiovascular risk factors as well as cardiovascular and noncardiovascular comorbidities increased across higher cTn strata. In total, 7,529 (15.4%) patients had a major adverse event (MAE), defined as the composite of all-cause mortality, myocardial infarction, readmission for heart failure, or stroke (median follow-up 4.9 years). MAE risk was associated with higher cTn strata (hazard ratio for highest assay-specific cTn tertile: 2.59; 95% confidence interval: 2.39 to 2.80; hazard ratio in patients without cardiovascular comorbidities, renal dysfunction, left ventricular dysfunction, or significant coronary stenosis: 3.57; 95% confidence interval: 2.30 to 5.54). CONCLUSIONS: cTn elevation is associated with cardiovascular and noncardiovascular comorbidities and predicts major adverse events in acutely admitted patients, in whom no definite diagnosis could have been established. The term troponinemia is trivializing and should be avoided. Instead, careful work-up is required in these patients.
引用
- Eggers KM, Jernberg T, Lindahl B, et al. Cardiac Troponin Elevation in Patients Without a Specific Diagnosis. J Am Coll Cardiol. 2019. PMID: 30621937. doi:10.1016/j.jacc.2018.09.082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。